Osteogenesis imperfektali yetişkin hastada zoledronik asit tedavisi: Bir olgu ve literatür derlemesi Zoledronic acid treatment in an adult patient with Osteogenesis Imperfecta: A case report and review of the literature

Osteogenesis Imperfecta (OI) is a rare heritable condition characterized by bone fragility and reduced bone mass. This pathology is characterized by disruption of biosynthesis of Type I collagen, and production of limited amount of defective and imperfect collagens. This causes decrease in bone mass of human body, bones become fragile and brittle, resulting in unreasonable multiple fractures. Other manifestations include hyperextensibility of the joints, blue sclera, hearing loss, short stature and dentinogenesis imperfecta. Bisphosphonates are now the most widely used for the treatment of OI. In conclusion, along with the literature, we present a case of zoledronic acid treatment in adult patient with OI. OZET Osteogenesis Imperfecta (OI) dusuk kemik kutlesi ve

[1]  E. Mattsson,et al.  Functioning and quality of life in adults with mild-to-moderate osteogenesis imperfecta. , 2013, Physiotherapy research international : the journal for researchers and clinicians in physical therapy.

[2]  C. Giunta,et al.  Recessive osteogenesis imperfecta: Clinical, radiological, and molecular findings , 2012, American journal of medical genetics. Part C, Seminars in medical genetics.

[3]  E. Eriksen,et al.  Bone mass, bone markers and prevalence of fractures in adults with osteogenesis imperfecta , 2011, Archives of osteoporosis.

[4]  J. N. Costa,et al.  An unusual presentation of osteogenesis imperfecta type I , 2011, International medical case reports journal.

[5]  S. Poyrazoglu,et al.  Successful Results of Pamidronate Treatment in Children With Osteogenesis Imperfecta With Emphasis on the Interpretation of Bone Mineral Density for Local Standards , 2008, Journal of pediatric orthopedics.

[6]  F. Glorieux,et al.  Osteogenesis Imperfecta: Update on presentation and management , 2008, Reviews in Endocrine and Metabolic Disorders.

[7]  J. Shapiro,et al.  Osteogenesis imperfecta: Epidemiology and pathophysiology , 2007, Current osteoporosis reports.

[8]  C. Cowell,et al.  Acute phase response and mineral status following low dose intravenous zoledronic acid in children. , 2007, Bone.

[9]  L. Elting,et al.  Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment. , 2006, The Lancet. Oncology.

[10]  F. Glorieux,et al.  Pamidronate in children with osteogenesis imperfecta: histomorphometric effects of long-term therapy. , 2006, The Journal of clinical endocrinology and metabolism.

[11]  F. Glorieux,et al.  Cyclical Intravenous Pamidronate Treatment Affects Metaphyseal Modeling in Growing Patients With Osteogenesis Imperfecta , 2005, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[12]  F. Glorieux,et al.  Delayed Osteotomy but Not Fracture Healing in Pediatric Osteogenesis Imperfecta Patients Receiving Pamidronate , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[13]  F. Glorieux,et al.  Respiratory distress with pamidronate treatment in infants with severe osteogenesis imperfecta. , 2004, Bone.

[14]  F. Glorieux,et al.  Height and weight development during four years of therapy with cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta types I, III, and IV. , 2003, Pediatrics.

[15]  F. Glorieux,et al.  Rapid increase in grip force after start of pamidronate therapy in children and adolescents with severe osteogenesis imperfecta. , 2003, Pediatrics.

[16]  F. Glorieux,et al.  Type V Osteogenesis Imperfecta: A New Form of Brittle Bone Disease , 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[17]  F. Glorieux,et al.  Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. , 1998, The New England journal of medicine.

[18]  D. Sillence,et al.  Genetic heterogeneity in osteogenesis imperfecta. , 1979, Journal of medical genetics.

[19]  J. Marini,et al.  Null mutations in LEPRE1 and CRTAP cause severe recessive osteogenesis imperfecta , 2009, Cell and Tissue Research.